A menopause service can address nutrition, symptoms and medicine in the same wider program without making them the same intervention. Gennev describes physician appointments and dietitian support. For a reader asking about progesterone, the useful starting point is who will explain the medicine’s purpose and what that explanation is based on.
This September 29, 2026 assessment considers Gennev’s public care and pricing information. It recognizes the clinical service while leaving the actual prescription, pharmacy product and personal benefit unconfirmed. No visit, benefits check or nutrition consultation was tested.
The physician and dietitian appointments answer different questions
Gennev’s care page describes medical care from menopause clinicians and support from registered dietitians. It says prescriptions may be provided when appropriate. Those statements verify a service, but not a standard package in which everyone receives progesterone or every professional makes medication decisions.
A discussion about food or lifestyle can coexist with a medical assessment without supplying the reason for a hormone prescription. Winona’s review examines a different model centered on asynchronous prescribing. Comparing those professional contacts is more informative than assuming that a broad program supplies a superior medicine or that nutrition support substitutes for an explanation of endometrial protection.
Begin by naming what the treatment is meant to change
The Gennev service description encompasses a range of menopause concerns. It does not establish that all are caused by a progesterone deficiency or that one medicine treats them all. A clinician needs to distinguish the concern that brought the patient to care from the purpose of each proposed intervention.
ACOG’s hormone-therapy guidance differentiates symptom treatment and the added progestogen role when relevant to estrogen therapy. Our systemic-estrogen discussion helps organize that distinction. This review cannot infer which role would apply merely from a person’s age, symptom description or the availability of prescription care through Gennev.
The existing estrogen record can change the question
FDA’s therapy categories separate systemic estrogen from topical vaginal treatment. Gennev’s reviewed pages do not assign an exact progesterone product to every estrogen option, and this assessment does not manufacture that connection. An existing medicine should be identified by its actual product and intended effect before another component is discussed.
The local-vaginal-estrogen guide explains why the route and exposure need attention. The 2020 NAMS abstract gives a specific low-dose vaginal-therapy distinction while acknowledging the absence of endometrial trials beyond one year. That is contextual professional evidence, not a confirmation of what Gennev would prescribe or permission to alter an existing plan.
A surgical history is information to interpret, not a treatment selector
ACOG explains that removal of the uterus and removal of the ovaries are distinct procedures, and that different hysterectomies remove different structures. The reviewed Gennev pages do not show a complete intake questionnaire, so this review cannot claim the service asks a particular sequence of surgical-history questions.
The after-hysterectomy guide supports a more precise conversation with the clinician. Prior surgery can be relevant without deciding treatment alone. A reader should not have to translate a remembered operation into a medicine rule. The actual clinical history and treatment objective belong together in the professional explanation of any added hormone.
Consultation prices are not medicine prices
The published fee table lists physician care at $250 for an initial visit and $199 for a follow-up. Dietitian visits are separately listed at $199 initially and $119 afterward. The physician appointment is described as thirty minutes. These amounts identify different professional services; they are not a monthly progesterone charge.
Insurance participation also does not establish what an individual owes. The page describes estimates before care and possible remaining balances after claims, with covered visit numbers dependent on the plan. MyMenopauseRx’s review supplies a useful comparison of another encounter-based service. Neither brand’s public fee table can determine the pharmacy cost of an unidentified prescription. A further useful distinction is who will answer a medication question between appointments. The presence of several professional services does not establish that each contact includes a prescriber’s review of a changed treatment goal.
A prescription sent promptly is not a completed treatment decision
Gennev’s service page describes prescriptions being sent to a pharmacy when indicated. That administrative step does not authenticate a particular capsule, confirm stock or establish the final quantity and ingredients. The person receiving care still needs to understand why the medicine was chosen and how it fits with existing treatment.
The reviewed records do not establish a universal renewal duration or progesterone follow-up interval. Nor do they provide complete cancellation and refund conditions for every selected encounter. Those unanswered questions matter when comparing ongoing care arrangements. A prompt transmission claim should not become a promise of same-day dispensing, continuing availability or a settled clinical outcome.
Reassessment needs a clinical route of its own
ACOG’s bleeding information says bleeding after menopause and abnormal changes warrant professional evaluation. The unexpected-bleeding guide keeps that task separate from a routine review of how a patient feels on a plan. An improved symptom score cannot itself explain a new bleeding pattern.
Gennev’s public offer gives a reader a documented place to seek menopause care, but does not establish a complete response pathway for every concern. A useful appointment would identify the treatment goal, the actual medicines, the professional responsible for reassessment and any needed local care. This review recognizes the service without assigning a product, declaring personal suitability or suggesting that nutrition counseling resolves a prescribing question.
Sources behind this article
Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.
- Gennev: virtual menopause careProvider physician and dietitian service; actual relevant prescribing, but no exact oral progesterone product or capsule formulary established · Checked 2026-09-29
- ACOG: Hormone Therapy for MenopauseUS specialty patient guidance; systemic and local exposure, treatment goals and clinical assessment, no personal regimen · Checked 2026-09-29
- FDA: Hormone Replacement Therapies Can Help Women with Bothersome Menopausal SymptomsCurrent federal categories and product-specific warning-change context; systemic estrogen and topical vaginal therapy distinguished, no class-wide warning conclusion · Checked 2026-09-29
- North American Menopause Society: 2020 Genitourinary Syndrome of Menopause position statementPublished professional consensus abstract only; low-dose vaginal therapy distinction, lack of endometrial trials beyond one year and breast-cancer evidence limits · Checked 2026-09-29
- ACOG: HysterectomyUS specialty patient guidance; uterus, cervix and ovary procedures distinguished, no treatment decision from surgery name alone · Checked 2026-09-29
- Gennev: insurance and pricingDated provider fee table and coverage process; doctor/dietitian initial/follow-up costs are separate from pharmacy charges · Checked 2026-09-28
- ACOG: Perimenopausal Bleeding and Bleeding After MenopauseUS specialty patient guidance reviewed February 2024; bleeding changes require professional assessment, not a site-generated workup or medication adjustment · Checked 2026-09-29